S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NYSE:NVO

Novo Nordisk A/S (NVO) Stock Forecast, Price & News

$107.75
+3.70 (+3.56%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$106.35
$108.22
50-Day Range
$102.45
$121.81
52-Week Range
$78.71
$122.16
Volume
2.30 million shs
Average Volume
1.73 million shs
Market Capitalization
N/A
P/E Ratio
32.07
Dividend Yield
1.42%
Beta
0.47
30 days | 90 days | 365 days | Advanced Chart
Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

Novo Nordisk A/S logo

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
45,000
Year Founded
1923

Sales & Book Value

Annual Sales
$22.40 billion
Cash Flow
$3.76 per share
Book Value
$4.78 per share

Profitability

Net Income
$7.60 billion
Pretax Margin
40.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Optionable

Company Calendar

Ex-Dividend for 4/5 Dividend
3/25/2022
Dividend Payable
4/05/2022
Last Earnings
4/29/2022
Today
5/21/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.52 out of 5 stars

Analyst Opinion: 4.2Community Rank: 4.0Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

Is Novo Nordisk A/S a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S
or view top-rated stocks.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,730,000 shares, a decrease of 47.1% from the April 15th total of 3,270,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.1% of the company's shares are sold short.
View Novo Nordisk A/S's Short Interest
.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) released its quarterly earnings data on Friday, April, 29th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.85 by $0.09. The company earned $6.34 billion during the quarter, compared to analysts' expectations of $5.82 billion. Novo Nordisk A/S had a net margin of 33.16% and a trailing twelve-month return on equity of 72.67%.
View Novo Nordisk A/S's earnings history
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a Semi-Annual dividend on Wednesday, March 2nd. Shareholders of record on Monday, March 28th will be given a dividend of $0.741 per share on Tuesday, April 5th. This represents a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, March 25th. This is a boost from Novo Nordisk A/S's previous Semi-Annual dividend of $0.56.
View Novo Nordisk A/S's dividend history
.

Is Novo Nordisk A/S a good dividend stock?

Novo Nordisk A/S pays an annual dividend of $1.48 per share and currently has a dividend yield of 1.42%. The dividend payout ratio of Novo Nordisk A/S is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 36.72% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2022 earnings guidance on Monday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $24.04 billion-$24.90 billion, compared to the consensus revenue estimate of $22.48 billion.

What price target have analysts set for NVO?

17 Wall Street analysts have issued 1 year target prices for Novo Nordisk A/S's shares. Their forecasts range from $130.00 to $900.00. On average, they expect Novo Nordisk A/S's stock price to reach $655.40 in the next twelve months. This suggests a possible upside of 508.3% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S
or view top-rated stocks among Wall Street analysts.

Who are Novo Nordisk A/S's key executives?
Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jorgensen, Pres, CEO & Member of Management Board (Age 56, Pay $5.2M)
  • Mr. Karsten Munk Knudsen, Exec. VP, CFO & Member of the Management Board (Age 51, Pay $1.92M)
  • Mr. Henrik Ehlers Wulff, Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board (Age 52, Pay $2.02M)
  • Ms. Camilla Sylvest, Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board (Age 50, Pay $1.92M)
  • Ms. Monique Carter, Exec. VP, Head of People & Organisation and Member of Management Board (Age 49, Pay $1.46M)
  • Mr. Maziar Mike Doustdar, Exec. VP, Head of International Operations & Member of the Management Board (Age 52)
  • Mr. Douglas J. Langa, Exec. VP, Head of North America Operations & Member of Management Board (Age 56)
  • Mr. Ludovic Helfgott, Exec. VP, Head of Rare Disease & Member of Management Board (Age 48)
  • Dr. Martin Holst Lange, Exec. VP, Head of Devel. & Member of the Management Board (Age 52)
  • Dr. Marcus Schindler Ph.D., EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board (Age 56)
What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.78%), Fisher Asset Management LLC (0.00%), Loomis Sayles & Co. L P (0.00%), Jennison Associates LLC (0.23%), Capital International Investors (0.00%) and BlackRock Inc. (0.21%).
View institutional ownership trends for Novo Nordisk A/S
.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Folketrygdfondet, Clearbridge Investments LLC, Renaissance Technologies LLC, Capital International Investors, Loomis Sayles & Co. L P, State Street Corp, UBS Group AG, and Grimes & Company Inc..
View insider buying and selling activity for Novo Nordisk A/S
or view top insider-selling stocks.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., Lord Abbett & CO. LLC, Twin Tree Management LP, Vantage Investment Partners LLC, Northern Trust Corp, Alyeska Investment Group L.P., and JPMorgan Chase & Co..
View insider buying and selling activity for Novo Nordisk A/S
or or view top insider-buying stocks.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $107.75.

How many employees does Novo Nordisk A/S have?

Novo Nordisk A/S employs 45,000 workers across the globe.

Does Novo Nordisk A/S have any subsidiaries?

The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., Calibrium, Churchill Stateside Solar Fund XIV LLC, Corvidia, Emisphere Technologies, MB2 LLC, NNE A/S, Novo Investment Pte Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk B.V., Novo Nordisk Biopharm Limited, Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comercio Produtos Farmaceuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungaria Kft., Novo Nordisk Inc., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZ-LLC, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Scandinavia AB, Novo Nordisk Scandinavia AS, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representacion C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, and Ziylo.

When was Novo Nordisk A/S founded?

Novo Nordisk A/S was founded in 1923.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at (454) 444-8888, via email at [email protected], or via fax at 45-4449-0555.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.